Starton Therapeutics (Starton Therapeutics) Debt-to-Asset : 0.37 (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Debt-to-Asset?

Starton Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.16 Mil. Starton Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $1.42 Mil. Starton Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $4.24 Mil. Starton Therapeutics's debt to asset for the quarter that ended in Jun. 2023 was 0.37.

Starton Therapeutics Debt-to-Asset Historical Data

The historical data trend for Starton Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics Debt-to-Asset Chart

Starton Therapeutics Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-Asset

0.19

0.67

0.75

Starton Therapeutics Quarterly Data
	Mar21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23
Debt-to-Asset	Get a 7-Day Free Trial			0.67	-	0.78	0.75	0.37

Competitive Comparison of Starton Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Starton Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Starton Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starton Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Starton Therapeutics's Debt-to-Asset falls into.

Starton Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Starton Therapeutics's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.161	+	1.451)	/	2.137
	=	0.75

Starton Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.157	+	1.421)	/	4.243
	=	0.37

Starton Therapeutics (NAS:STA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Starton Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Starton Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Starton Therapeutics (Starton Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 College Road, Suite No.300, Paramus, NJ, USA, 07652

Website

https://www.startontx.com

Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines